CN118475611A - 抗btn3a治疗的应答者选择 - Google Patents

抗btn3a治疗的应答者选择 Download PDF

Info

Publication number
CN118475611A
CN118475611A CN202280062098.6A CN202280062098A CN118475611A CN 118475611 A CN118475611 A CN 118475611A CN 202280062098 A CN202280062098 A CN 202280062098A CN 118475611 A CN118475611 A CN 118475611A
Authority
CN
China
Prior art keywords
antibody
btn
cells
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280062098.6A
Other languages
English (en)
Chinese (zh)
Inventor
E·瓦伦丁
P·弗罗纳
A·德盖萨特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Induction Therapy Co
Original Assignee
Induction Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Induction Therapy Co filed Critical Induction Therapy Co
Publication of CN118475611A publication Critical patent/CN118475611A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280062098.6A 2021-09-15 2022-09-15 抗btn3a治疗的应答者选择 Pending CN118475611A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306272 2021-09-15
EP21306272.2 2021-09-15
PCT/EP2022/075608 WO2023041622A1 (en) 2021-09-15 2022-09-15 Selection of responders for anti-btn3a treatment

Publications (1)

Publication Number Publication Date
CN118475611A true CN118475611A (zh) 2024-08-09

Family

ID=77998935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280062098.6A Pending CN118475611A (zh) 2021-09-15 2022-09-15 抗btn3a治疗的应答者选择

Country Status (6)

Country Link
US (1) US20230227558A1 (https=)
EP (1) EP4401837A1 (https=)
JP (1) JP2024533067A (https=)
CN (1) CN118475611A (https=)
TW (1) TW202313695A (https=)
WO (1) WO2023041622A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20260034T1 (hr) * 2018-08-01 2026-02-27 Imcheck Therapeutics Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja
JP2026506893A (ja) * 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
TW202506731A (zh) * 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
WO2024251981A1 (en) * 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024261239A1 (en) * 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
HRP20260034T1 (hr) 2018-08-01 2026-02-27 Imcheck Therapeutics Anti-btn3a antitijela i njihova upotreba u liječenju raka ili infektivnih poremećaja

Also Published As

Publication number Publication date
JP2024533067A (ja) 2024-09-12
EP4401837A1 (en) 2024-07-24
US20230227558A1 (en) 2023-07-20
TW202313695A (zh) 2023-04-01
WO2023041622A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
US20240002515A1 (en) Methods and antibodies for modulation of immunoresponse
JP6839761B2 (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
CN109563165B (zh) 抗ctla-4抗体
CN107530428B (zh) Icos的抗体
US20230227558A1 (en) Selection of responders for anti-btn3a treatment
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
JP2019517773A (ja) 抗ｌａｇ−３抗体
JP2018525367A (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
JP6661019B2 (ja) イヌ抗ｃｄ２０抗体
AU2021315882A1 (en) Compositions including ex vivo armed T cells with multi-specific antibodies and uses thereof
EP4292611A1 (en) Anti-cd112r antibody and use thereof
US20240368301A1 (en) MONOCLONAL ANTIBODY TARGETING SIRPa AND USE THEREOF
AU2020287327A1 (en) Treatment of cancers with GM-CSF antagonists
CN115785268A (zh) 抗cd47抗体及其用途
JP2022529340A (ja) ヒトｃｄ４７を標的とする抗体
US20260098093A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
JP2021014449A (ja) Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
CN120813377A (zh) Btn3a活化抗体和免疫检查点抑制剂的组合
EP4265639A2 (en) Anti-hvem antibody, and composition and method associated with same
KR20250080883A (ko) 암 치료에 사용하기 위한 BTN3A 활성화 항체, Bcl-2 억제제 및 저메틸화제의 조합
TW202333786A (zh) 逆轉treml1誘導之免疫抑制之方法
HK40000388A (en) Anti-ctla-4 antibodies
HK1248127B (en) Antibodies to icos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination